EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Rapidly Progressive Overlap of Immune Checkpoint Inhibitor-Induced Myositis and Myasthenia Gravis: Diagnostic and Therapeutic Challenges

Sofia Sequeira, Catarina Borges, Paulo Castro, Nelson Barros, Michel Mendes

Cureus · 31.01.2026

DOI: 10.7759/cureus.102739 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cureus, erschienen am 31.01.2026. Verfasst von Sofia Sequeira und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Hospital de Santo Espírito da Ilha Terceira, Angra do Heroísmo, PRT. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) are increasingly used across advanced malignancies but may precipitate severe immune-related neuromuscular toxicities, particularly with combination regimens. We report a fulminant case of overlap syndrome involving ICI-induced myositis and myasthenia gravis in a 72-year-old man receiving ipilimumab-nivolumab for hepatocellular carcinoma and recurrent renal cell carcinoma. Shortly after the second cycle, he developed rapidly progressive ophthalmoparesis, bulbar dysfunction, myalgias, and proximal tetraparesis. Laboratory studies revealed marked elevations of creatine kinase, myoglobin, and troponin, and electromyography demonstrated a myopathic pattern with active denervation. Acetylcholine receptor antibodies were positive, raising suspicion for a concomitant ICI-associated myasthenic component within an overlap neuromuscular syndrome. Despite prompt intensive care admission and treatment with high-dose intravenous methylprednisolone and intravenous immunoglobulin, only partial clinical improvement was achieved. The subsequent development of aspiration pneumonia led to acute respiratory and hepatic failure, culminating in death. This case underscores the aggressive clinical trajectory and high mortality of ICI-related neuromuscular overlap syndromes, highlighting the critical need for early recognition, rapid immunosuppression, and multidisciplinary management.

Schlagwörter

Stichwörter der Autor:innen

immune-checkpoint inhibitorsimmune-related adverse eventsmyasthenia gravismyositisneuromuscular toxicityoverlap syndrome

Autor:innen und Institutionen

  • Internal Medicine, Hospital de Santo Espírito da Ilha Terceira, Angra do Heroísmo, PRT.
  • Neurology, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, PRT.
  • Oncology, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, PRT.
  • Intensive Care Medicine, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, PRT.

Zitieren

APA

Sequeira, S., Borges, C., Castro, P., Barros, N., & Mendes, M. (2026). Rapidly Progressive Overlap of Immune Checkpoint Inhibitor-Induced Myositis and Myasthenia Gravis: Diagnostic and Therapeutic Challenges. Cureus. https://doi.org/10.7759/cureus.102739

Vancouver

Sequeira S, Borges C, Castro P, Barros N, Mendes M. Rapidly Progressive Overlap of Immune Checkpoint Inhibitor-Induced Myositis and Myasthenia Gravis: Diagnostic and Therapeutic Challenges. Cureus. 2026. doi:10.7759/cureus.102739

BibTeX
@article{Sequeira2026,
  author = {Sequeira, Sofia and Borges, Catarina and Castro, Paulo and Barros, Nelson and Mendes, Michel},
  title = {Rapidly Progressive Overlap of Immune Checkpoint Inhibitor-Induced Myositis and Myasthenia Gravis: Diagnostic and Therapeutic Challenges},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.102739}
}
Kostenlos starten →